Clinical Takeaway GLP-1 plateaus happen because the body adapts by slowing metabolism and increasing hunger signals over time. Clinicians may adjust dosing, add adjunct therapies, or address behavioral factors to push past...
Same Drug, Different Goals: GLP-1s Treat More Than Sugar
Clinical Takeaway GLP-1 medications like semaglutide are FDA-approved for both type 2 diabetes management and chronic weight loss, but the target doses, titration schedules, and treatment goals can differ significantly between the...
GLP-1 Receptor Agonist Clinical Evidence: Mental Health Links
GLP-1 Clinical Relevance #42Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic GLP-1 Mental HealthSemaglutide Psychiatric EffectsOzempic Brain BenefitsGLP-1 Mood ResearchMetabolic Mental Wellness Why This Matters Family...
GLP-1 Receptor Agonist Evidence Amid Gray Market Concerns
GLP-1 Clinical Relevance #45Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic GLP-1 Gray MarketPeptide Regulatory PolicyCompounded Obesity DrugsRFK Metabolic AgendaExperimental Weight Loss Access...
GLP-1 Receptor Agonist Evidence: Weight Loss & Marriage Risk
GLP-1 Clinical Relevance #48Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic GLP-1 Relationship EffectsWeight Loss Divorce RiskOzempic Social ConsequencesMetabolic Therapy Marriage ImpactGLP-1 Psychosocial...
Cannabis and Sleep: A Proposed Self-Reinforcing Cycle That May Worsen Both
Sleep problems prompt self-medication with cannabis, which inadvertently maintains or worsens sleep problems due to predictable neurobiological processes. Over time, self-medication behavior may increase to compensate for cannabis tolerance and ongoing sleep problems, ultimately increasing risk for cannabis use disorder and associated consequences.
This narrative review examines whether the endocannabinoid system may play a biochemical role in ADHD pathophysiology. It gathers 11 preclinical and 2 clinical studies and argues that ECS signaling may intersect with attention, impulsivity, and hyperactivity pathways. The core limitation is that the evidence remains thin, heavily preclinical, and far from proving that cannabinoid-based treatments are ready for clinical use in ADHD.
Cannabis and Sleep: A Self-Reinforcing Cycle That May Worsen Both
Sleep problems prompt self-medication with cannabis, which inadvertently maintains or worsens sleep problems due to predictable neurobiological processes. Over time, self-medication behavior may increase to compensate for cannabis tolerance and ongoing sleep problems, ultimately increasing risk for cannabis use disorder and associated consequences.
Cannabis and the Heart and Vessels: What the Science Actually Says
Although existing literature suggests a direct role of cannabinoids in the pathogenesis of atherosclerosis, the correlation between cannabinoids and other vascular diseases was only reported in some case series or observational studies, and its role and precise mechanisms remain unclear.